| ARTL Stock | | | USD 2.31 -0.09 -3.75% |
Artelo Biosciences' Net Asset is shown below with the definition, formula, and latest reported value. The formula breaks the metric into its component accounting inputs. Net Asset is the value of fund assets after liabilities are deducted. It is the balance-sheet foundation behind net asset value, or NAV.
Net Asset | = | Total Assets | - | Total Liabilities |
| = | 2.8 M | |
For funds and ETFs, net assets help frame scale, liquidity, and staying power. In closed-end or thinly traded products, price can still move away from NAV for long stretches. This Net Asset figure for Artelo Biosciences is based on recent reported data. The dataset is maintained in line with ongoing disclosure updates.
Peer analysis of Artelo Biosciences using Net Asset surfaces how it ranks against direct and indirect competitors. Significant differences in Artelo Biosciences' Net Asset versus peers can highlight competitive strengths or weaknesses. Relative Net Asset analysis across the peer group reveals valuation patterns that absolute metrics cannot capture.
Artelo Biosciences's core fundamentals cover profitability, capital efficiency, and funding structure. Cash reserves provide a direct read on near-term financial cushion. In recent filings, Artelo Biosciences reported EPS loss of 37.56, current ratio of 42.28, debt-to-equity of 0.0 as of the latest reporting period.
Artelo Biosciences metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. Income statement, balance sheet, and cash-flow values follow GAAP or IFRS conventions as reported.
Editorial review and methodology oversight provided by:
Raphi Shpitalnik, Junior Member of Macroaxis Editorial Board